An abnormal but functionally active complement component C9 protein found in an Irish family with subtotal C9 deficiency

Immunology

Volumn 108, Issue 3, 2003, Pages 384-390

  Orren, Ann ^a,b   O'Hara, Ann M ^a,d   Morgan, B Paul ^b   Moran, Anthony P ^a   Würzner, Reinhard ^c  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF INNSBRUCK   (Austria)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C9; CYSTEINE; GLYCINE; LIPOPOLYSACCHARIDE; LIPOPROTEIN RECEPTOR; MONOCLONAL ANTIBODY;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; BACTERICIDAL ACTIVITY; BINDING SITE; CASE REPORT; COMPLEMENT DEFICIENCY; EPITOPE MAPPING; ESCHERICHIA COLI; FAMILIAL DISEASE; FEMALE; GENETIC DISORDER; HEMOLYSIS; HUMAN; IMMUNOREACTIVITY; IRELAND; MALE; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEFECT; PROTEIN FUNCTION;

AGED; BLOOD BACTERICIDAL ACTIVITY; COMPLEMENT C9; COMPLEMENT MEMBRANE ATTACK COMPLEX; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; FEMALE; HEMOLYSIS; HUMANS; LIPOPOLYSACCHARIDES; MALE; MUTATION;

EID: 0037342617     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.2003.01587.x     Document Type: Article

References (38)

1. Podack ER, Tschopp J, Müller-Eberhard HJ. Molecular organization of C9 within the membrane attack complex of complement: induction of circular C9 polymerization by the C5b-9 assembly. J Exp Med 1982; 156:268-82.
2. Podack ER, Tschopp J. Polymerization of the ninth component of complement (C9): formation of poly (C9) with a tubular ultrastructure resembling the membrane attack complex of complement. Proc Natl Acad Sci USA 1982; 79:574-8.
3. Morgan BP. Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects. Biochem J 1989; 264:1-14.
4. Joiner KA, Schmetz MA, Sanders ME, Murray TG, Hammer CH. Dourmaskin R, Frank MM. Multimeric complement component C9 is necessary for killing of Escherichia coli J5 by terminal attack complex C5b-9. Proc Natl Acad Sci USA 1985; 82:4808-12.
5. O'Hara AM, Moran AP, Würzner R, Orren A. Complement-mediated lipopolysaccharide release and outer membrane damage in Escherichia coli J5: requirement for C9. Immunology 2001; 102:365-72.
6. Stolfi RL. Immune lytic transformation. A state of irreversible damage generated as a result of the reaction of the eighth component in guinea pig complement system. J Immunol 1968; 100:46-54.
7. Stanley KK, Kocher HP, Luzio JP, Jackson P. Tschopp J. The sequence and topology of human complement component C9. EMBO J 1985; 4:375-82.
8. Stanley KK, Herz J. Topological mapping of complement C9 by recombinant DNA techniques suggest a novel mechanism for its insertion into target membranes. EMBO J 1987; 6:1951-7.
9. Plumb ME, Sodetz JM. Proteins of the Membrane Attack Complex. In: Volanakis JE, Frank MM, eds. The Human Complement System in Health and Disease. New York: Dekker, 1998: 119-48.
10. DiScipio RG, Gehring MR, Podack ER, Kan CC, Hugli TE, Fey GH. Nucleotide sequence of cDNA and derived amino acid sequence of human complement component C9. Proc Natl Acad Sci USA 1984; 81:7298-302.
11. Lengweiler S, Schaller J, Rickli EE. Identification of disulphide bonds in the ninth component (C9) of human complement. FEBS Lett 1996; 380:8-12.
12. Fukumori Y, Yoshimura K, Ohnoki S, Yamaguchi H, Akagaki Y, Inai S. A high incidence of C9 deficiency among healthy blood donors in Osaka, Japan. Int Immunol 1989; 1:85-9.
13. Nagata M, Hara T, Aoki T, Mizuno Y, Akeda H, Inaba S, Tsumoto K, Ueda K. Inherited deficiency of ninth component of complement: an increased risk of meningococcal meningitis. J Pediatr 1989: 114:260-4.
14. Würzner R, Orren A, Lachmann PJ. Inherited deficiencies of the terminal components of human complement. Immunodeficiency Rev 1992; 3:123-47.
15. Witzel-Schlömp K, Späth PJ, Hobart MJ, Fernie BA, Rittner C, Kaufmann T. Schneider PM. The human complement C9 gene. Identification of two mutations causing deficiency and revision of gene structure. J Immunol 1997; 158:5043-9.
16. Kira R, Ihara K, Takada H, Gondo K, Hara T. Nonsense mutation in exon 4 of human complement C9 gene is the major cause of Japanese complement C9 deficiency. Hum Genet 1998; 102:605-10.
17. Witzel-Schlömp K, Hobart MJ, Fernie BA, Orren A, Würzner R, Rittner C, Kaufmann T. Schneider PM. Heterogeneity in the genetic basis of human complement C9 deficiency. Immunogenetics 1998; 48:144-7.
18. Orren A, Würzner R, Potter PC, Fernie BA, Coetzee S, Morgan BP, Lachmann PJ. Properties of a low molecular weight complement component C6 found in human subjects with subtotal C6 deficiency. Immunology 1992; 75:10-6.
19. Harrison RA, Lachmann PJ. Complement technology. In: Weir DM, ed. Handbook of Experimental Immunology, Vol. I. Oxford: Blackwell Scientific Publications. 1986: 39.1-49.
20. Egan LJ, Orren A, Doherty J, Würzner R, McCarthy CF. Hereditary deficiency of the seventh component of complement and recurrent meningococcal infection: investigations in an Irish family using a novel haemolytic screening assay for complement activity and C7 M/N allotyping. Epidemiol Infect 1994; 113:275-81.
21. Hobart MJ. Fernie BA, Würzner R. Oldroyd RG, Harrison RA, Joysey V, Lachmann PJ. Difficulties in the ascertainment of C9 deficiency: lessons to be drawn from a compound heterozygote C9-deficient subject. Clin Exp Immunol 1997; 108:500-6.
22. Orren A, Potter PC, Cooper R, du Toit E. Deficiency of the sixth component of complement and susceptibility to Neisseria meningitidis infections. Studies in ten families and five isolated cases. Immunology 1987; 62:249-53.
23. O'Hara AM. Fernie BA, Moran AP, Williams YE, Connaughton JJ, Orren A, Hobart MJ. C7 deficiency in an Irish family: a deletion defect which is predominant in the Irish. Clin Exp Immunol 1998; 114:355-61.
24. Morgan BP, Daw RA, Siddle K, Luzio JP, Campbell AK. Immunoaffinity purification of human complement C9 using monoclonal antibodies. J Immunol Meth 1983; 64:269-81.
25. Würzner R, Schulze M, Happe L, Franzke A, Bieber FA, Oppermann M, Götze O. Inhibition of terminal complement complex formation and cell lysis by monoclonal antibodies. Complement Inflamm 1991; 8:328-40.
26. Würzner R, Orren A, Potter P et al. Functionally active complement proteins C6 and C7 detected in C6- and C7-deficient individuals. Clin Exp Immunol 1991; 83:430-7.
27. Laemmli UK. Cleavage of structural proteins during assembly of the head of bacteriophage T4. Nature 1970; 227:680-5.
28. Towbin H, Staehelin T, Gordon I. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979; 76:4350-4.
29. Orren A, Lerch WH, Dowdle EB. Functional identification of serum complement components following electrophoresis in polyacrylamide gels containing sodium dodecyl sulphate. J Immunol Meth 1983; 59:63-71.
30. Hobart MJ, Lachmann PJ, Alper CA. Polymorpbism of human C6. In: Peeters H, ed. Protides of the Biological Fluids. Oxford: Pergamon Press, 1975:575-80.
31. Elbein AD, Heath EC. lhe biosynthesis of cell wall lipopolysaccharide in Escherichia coli. I. The biochemical properties of a uridine diphosphate galactose-4-epimeraseless mutant. J Biol Chem 1965; 240:1919-25.
32. Appelmelk BJ, Maaskant JJ, Verrweij-van Vught MJJ, van der Meer NM, Thijs BG. MacLaren DM. Antigenic and immunogenic differences in lipopolysaccharides of Escherichia coli J5 vaccine strains of different origins. J Gen Microbiol 1993; 139:2641-7.
33. Leive L. Actinomycin sensitivity in Escherichia coli produced by EDTA. Biochem Biophys Res Commun 1965; 18:13-7.
34. Taylor KM, Trimby AR, Campbell AK. Mutation of recombinant complement component C9 reveals the significance of the N-terminal region for polymerization. Immunology 1977; 91:20-7.
35. Bieri S, Djordjevic JT, Daly NL, Smith R, Kroon PA. Disufide bridges of a cysteine-rich repeat of the LDL receptor ligand-binding domain. Biochemistry 1995; 34:13059-65.
36. Daly NL, Scanlon MJ, Djordjevic JT, Kroon PA, Smith R. Three-dimensional structure of a cysteine-rich repeat from the low-density lipoprotein receptor. Proc Natl Acad Sci USA 1995; 92:6334-8.
37. Rosenfeld SI, Packman CH, Leddy JP. Inhibition of the lytic action of cell-bound terminal complement components by human high density lipoproteins and apoproteins. J Clin Invest 1983; 71:795-808.
38. Dupuis M, Peitsch MC. Hamann U, Stanley KK, Tschopp J. Mutations in the putative lipid-interaction domain of complement C9 result in defective secretion of the functional protein. Mol Immunol 1993; 30:95-100.